Literature DB >> 3141047

Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.

G K Needham1, S Nicholson, B Angus, J R Farndon, A L Harris.   

Abstract

The total plasminogen activator (PA) activity and the activities of urokinase type (uPA) and tissue type (tPA) plasminogen activators were measured in 43 primary human breast cancer homogenates. The majority of the PA activity was found in the 100,000 X g crude membrane pellets (log mean of 490 milli-IU/mg of protein, +1169, -346), and little PA activity was present in the cytosolic supernatant (log mean of 19 milli-IU/mg of protein, +168, -17). The activities of total PA and of each type of PA were compared to the estrogen receptor (ER) and epidermal growth factor receptor (EGFR) status of the tumors and to their histological grade. Total PA activity and uPA activity were not significantly different in any group of tumors stratified according to receptor status or tumor grade. Tissue type PA levels, however, were significantly lower in ER-negative compared with ER-positive tumors and in EGFR-positive compared with EGFR-negative tumors (P less than 0.01 and less than 0.05, respectively). The tPA activity was also related to grade, decreasing with worsening differentiation (P = 0.04). The ER-negative tumors were further stratified into EGFR-positive and -negative subgroups. Only the ER-negative tumors possessing EGFR had significantly lower tPA levels than the ER-positive tumors (P less than 0.01). Low tPA levels in breast cancers were, therefore, associated with ER negativity combined with EGFR positivity and may be an indication of poorer differentiation and prognosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141047

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.

Authors:  Hernán G Farina; Débora R Bublik; Daniel F Alonso; Daniel E Gomez
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  The epidermal growth factor receptor in breast cancer.

Authors:  S B Fox; A L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival.

Authors:  S B Fox; R D Leek; K Smith; J Hollyer; M Greenall; A L Harris
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

4.  Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.

Authors:  I Eto; C J Grubbs
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

Review 5.  Hemostatic changes in patients with brain tumors.

Authors:  L Thoron; E Arbit
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.

Authors:  E F Solomayer; I J Diel; D Wallwiener; S Bode; G Meyberg; M Sillem; C Gollan; M D Kramer; U Krainick; G Bastert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis.

Authors:  S Kakolyris; L Kaklamanis; K Engels; S B Fox; M Taylor; I D Hickson; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.

Authors:  J H de Witte; C G Sweep; J G Klijn; N Grebenschikov; H A Peters; M P Look; T H van Tienoven; J J Heuvel; J Bolt-De Vries; T J Benraad; J A Foekens
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium.

Authors:  S B Fox; M Westwood; A Moghaddam; M Comley; H Turley; R M Whitehouse; R Bicknell; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.